Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M
Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.
Tempest Therapeutics Research Collaboration with Heibei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics entered into an exclusive collaboration and option agreement with Heibei Senlang Biotechnology to develop and commercialize an in vivo CAR-T technology platform worldwide, excluding Greater China. Tempest paid an option fee of approximately $0.447 million for a four-month window to license the technology, which includes a Phase 1 dual-targeting candidate for multiple myeloma. The deal establishes Tempest as a multi-platform in vivo CAR-T company, combining Senlang's lentiviral vector platform with Tempest's existing LNP delivery technology.